Ansell manufactures personal protective equipment—primarily gloves for industrial and healthcare markets across 88 countries. At A$31.07 versus fair value A$34.46, the stock offers 10.9% upside. The key driver is whether the group's current 14.3% EBIT margin—elevated by the KBU acquisition and cost savings—proves structural or reverts toward the 12% historical average as competitive pressures and tariff policies normalise.

Best fit: Thematic and value investors. The stock suits investors seeking exposure to defensive industrials benefiting from consolidation and regulatory trends, combined with a modest valuation discount that limits downside. The 2-3 year time horizon required to realise value makes this unsuitable for traders or growth-focused portfolios.

Ansell manufactures personal protective equipment—primarily gloves for industrial and healthcare applications. The business generates revenue through consumable products that require repeat purchase: safety gloves for manufacturing workers, surgical gloves for hospitals, and cleanroom gloves for semiconductor facilities. Revenue splits roughly evenly between industrial (46%) and healthcare (54%) segments across 88 countries.

The first half of FY26 delivered adjusted EBIT margins of 14.3%, a 220 basis point improvement from the pre-acquisition baseline. This expansion came from two sources: the KBU acquisition added US$274 million in revenue at 27.5% EBIT margins, and the completed APIP cost program locked in US$50 million in structural savings. Management successfully offset US$80 million in annualised tariffs through pricing, demonstrating the portfolio's defensive characteristics.

The investment case centres on margin sustainability rather than growth. If the 14%+ EBIT margin proves structural—supported by KBU's premium product mix and embedded cost savings—the current valuation is attractive. The counterargument is mean reversion: competitors may respond to pricing, tariff policies could reverse, and industrial volumes are contracting (down 0.6% organically in H1). At A$31.07 versus fair value A$34.46, the stock is 10.9% undervalued.

The first half of FY26 showed bifurcated performance. Revenue grew 2.8% as tariff-driven price increases masked underlying volume weakness—organic constant currency growth was negative 0.6%. EBIT margins expanded to 14.3% as KBU integration synergies and APIP cost savings more than offset the volume headwinds. Healthcare performed better than Industrial, growing 3.8% versus 1.7%, as surgical and cleanroom segments benefited from stable hospital budgets and semiconductor facility expansions. Free cash flow conversion spiked to 112% in the half due to working capital timing, though this will normalise to 85% over the full year.

The outlook depends on two inflection points. First, whether industrial volumes recover in the second half—management guided for positive organic growth, though this requires PMI readings above 51 and stabilisation in automotive manufacturing. Second, whether margins hold at 14%+ as the remaining US$10 million in KBU synergies are captured by FY27. The key catalyst arrives in August 2026 with full-year results under new CEO Nathalie Ahlström, providing the first evidence of strategic continuity. Tariff policy remains the wildcard—a reversal would unwind pricing gains within 6-12 months.

The thesis breaks if the US tariff regime reverses. Ansell offset US$80 million in annualised tariffs by raising prices across its portfolio—a move enabled by the tariff umbrella that made competitor products equally expensive. If tariff rates fall by 20% or more, pricing discipline evaporates. Competitors with single-country manufacturing (primarily Southeast Asian) regain their cost advantage, forcing Ansell to cut prices. The company's 14-plant, seven-country network provides some flexibility, but reallocating production takes 6-12 months. A tariff reversal would reduce EBIT by US$30-40 million (14% of earnings), compressing fair value to approximately A$29—below the current price. This scenario carries 25% probability and represents the primary downside catalyst over the next two years.